Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Xvivo Perfusion
466,5
SEK
+0,65 %
XVIVO
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Alle 1K seuraajaa
+0,65%
+4,83%
−4,6%
+4,36%
−10,29%
+69,95%
+92,77%
+180,69%
+2 355,26%
Xvivo Perfusion is a medical technology company. The company provides solutions for lung transplantation. Examples of products that the company delivers include needles, organ storage, and cooling solutions. The products are resold to clinics and research institutes around the global market, with the largest business presence in the Nordics and Europe. The company was established via a spin-off from Vitrolife in 2012 and is headquartered in Gothenburg.
Lue lisääMarkkina-arvo
14,69 mrd. SEK
Vaihto
3,53 milj. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Pörssikalenteri
24.4.
2025
Osavuosikatsaus Q1'25
25.4.
2025
Yhtiökokous '25
11.7.
2025
Osavuosikatsaus Q2'25
NäytäKaikki sisältötyypit

XVIVO, Audiocast with teleconference, Q4'24
Year-end report 2024
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q4 2024
Conference call on Year-end Report 2024
Enrollment completed five months early in the US clinical trial evaluating XVIVO’s heart preservation technology
XVIVO Perfusion appoints Lena Hagman as deputy CEO
Redeye: XVIVO Update - Excellent organic growth and a negative currency surprise

XVIVO, Audiocast with teleconference, Q3'24
Interim report January-September 2024
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2024
Conference call on Interim Report
XVIVO to acquire a unique communication platform for the transplant process
Nomination Committee of XVIVO Perfusion AB (publ)
Results from European randomized controlled study using XVIVO’s heart technology published in The Lancet
Redeye: XVIVO Q2 Update - Another roaring quarter
